FAQs about the Inflation Reduction Act’s Medicare Drug Price Negotiation Program January 23, 2025 Issue Brief The Centers for Medicare & Medicaid Services (CMS) recently announced the drugs selected for the second round of negotiation for the Medicare Drug Price Negotiation Program, which was established by the Inflation Reduction Act. These FAQs address several questions related to Medicare’s drug price negotiation program and CMS’s implementation of the program, with a focus on the details that apply for 2027, the second year that negotiated prices will be available under the program.
Medicare Part D Enrollees Without Low-Income Subsidies (LIS) With Drug Spending Above the Catastrophic Threshold January 19, 2024 State Indicator
KFF Prescription Drug Advertisements Poll: January 2025 February 11, 2025 Poll Finding KFF’s January 2025 Prescription Drug Advertisements Poll looks at the public’s experiences with prescription drug advertisements, whether they’ve talked to a doctor about advertised drugs, and how this has influenced the care they receive.
A Look at Changes in Opioid Prescribing Patterns in Medicaid from 2016 to 2019 February 17, 2023 Issue Brief This analysis builds on previous KFF work by using Medicaid claims data for 2016-2019 to explore how prescriptions for opioids used to treat pain and those used to treat OUD or rapidly reverse overdose changed across states and Medicaid enrollee demographic groups over time.
KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs May 10, 2024 Poll Finding KFF’s latest Health Tracking Poll examines the public’s views and use of an an increasingly popular class of prescription drugs used for weight loss and to treat diabetes or prevent heart attacks or strokes. The poll finds 12% of adults report having taken one of these GLP-1 drugs, which include Ozempic, Webovy and Mounjaro. This includes 6% who say they are currently taking one of the drugs.
Poll: 1 in 8 Adults Say They’ve Taken a GLP-1 Drug, Including 4 in 10 of Those with Diabetes and 1 in 4 of Those with Heart Disease May 10, 2024 News Release About one in eight adults (12%) say they have taken one of an increasingly popular class of prescription drugs known as GLP-1s that are used for weight loss and to treat diabetes and reduce the risk of heart disease and stroke, a new KFF Health Tracking Poll finds. This includes…
Costly GLP-1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans June 12, 2024 News Release Affordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a new KFF analysis of 2024 federal plan data. Wegovy, a drug that is approved for weight loss, is covered by just 1% of Marketplace prescription drug plans, compared to 82% of Marketplace…
Key Facts About Medicare Part D Enrollment, Premiums, and Cost Sharing in 2024 July 2, 2024 Issue Brief This brief analyzes 2024 Medicare Part D enrollment, premiums, and cost sharing. The analysis highlights the continued growth in Medicare Advantage enrollment in the Part D marketplace and substantially higher average monthly premiums for stand-alone Part D drug plan coverage. Changes to the Part D benefit included in the Inflation Reduction Act are helping to lower out-of-pocket costs for patients but could also contribute to higher-priced Part D coverage.
How Medicare Negotiated Drug Prices Compare to Other Countries December 19, 2024 Issue Brief This analysis finds that Medicare’s negotiated prices for 10 high-expenditure prescription drugs are lower than what private Medicare drug plans had been paying, but still much higher than the prices available in 11 other wealthy nations.. It is available on the Peterson-KFF Health System Tracker.
Potential Health Policy Administrative Actions Under President Biden December 8, 2020 Issue Brief This brief outlines the potential health policy actions that President Biden could take using executive authority, based on campaign pledges, and actions that would reverse or modify regulations or guidance issued by the Trump Administration.